Skip to content

The role of aldosterone in cardiovascular disease in chronic renal failure

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN37814228
Enrollment
200
Registered
2005-09-30
Start date
2005-03-23
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular: Associated with renal failure Circulatory System Associated with renal failure

Interventions

The study has been designed after extensive consultation with our very experienced multidisciplinary renal research team. This will be a randomised, double-blind, placebo-controlled study of the effec
1 teaspoon) to monitor blood potassium levels and should take no longer than 10 minutes. The 3 main visits will each last approximately 2 hours. They will happen right at the beginning, after 4 weeks

Sponsors

Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Not provided at time of registration

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
1. Arterial stiffness after 40 weeks of spironolactone/placebo 2. Left ventricular mass, systolic & diastolic dysfunction, heart rate variability, endothelial dysfunction, plasma oxidant and inflammatory markers

Secondary

MeasureTime frame
Not provided at time of registration

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026